Dilanubicel - Nohla Therapeutics
Alternative Names: Ex vivo expanded universal donor cellular therapies - Nohla Therapeutics; Ex vivo-expanded cord blood progenitor cells; Haematopoetic progenitor cell therapy - Nohla Therapeutics; Haematopoetic-stem-cell-therapy-Nohla-Therapeutics; NLA 101; Notch-mediated ex vivo expanded cord blood HSPC - Nohla TherapeuticsLatest Information Update: 09 Feb 2024
At a glance
- Originator Fred Hutchinson Cancer Research Center
- Developer Fred Hutchinson Cancer Research Center; National Cancer Institute (USA); National Heart, Lung and Blood Institute; Nohla Therapeutics
- Class Antineoplastics; Haematopoietic stem cells therapies; Immunotherapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Acute myeloid leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Neutropenia
- No development reported Acute radiation syndrome; Graft-versus-host disease; Transplant rejection
Most Recent Events
- 24 Jan 2024 Nohla Therapeutics reinitiates enrollment a phase II trial in Myelodysplastic syndromes, Chronic myeloid leukaemia, Acute myeloid leukaemia (In adults, In the elderly, Second-line therapy or greater) and Haematological malignancies in USA (IV) (NCT03399773)
- 10 Jan 2024 Nohla Therapeutics suspends a phase II trial in Myelodysplastic syndromes, Chronic myeloid leukaemia, Acute myeloid leukaemia (In adults, In the elderly, Second-line therapy or greater) and Haematological malignancies in USA (IV) as study met its initial enrollment goal and researchers are modifying study to expand enrollment (NCT03399773)
- 28 Aug 2022 No recent reports of development identified for preclinical development in Transplant-rejection in USA (IV)